AR106332A1 - Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona - Google Patents

Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona

Info

Publication number
AR106332A1
AR106332A1 ARP160103122A ARP160103122A AR106332A1 AR 106332 A1 AR106332 A1 AR 106332A1 AR P160103122 A ARP160103122 A AR P160103122A AR P160103122 A ARP160103122 A AR P160103122A AR 106332 A1 AR106332 A1 AR 106332A1
Authority
AR
Argentina
Prior art keywords
dihydroisoquinolin
methylbutyl
hydroxy
methyl
crystalline form
Prior art date
Application number
ARP160103122A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR106332A1 publication Critical patent/AR106332A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Abstract

Reivindicación 1: Una forma cristalina caracterizada porque es de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona. Reivindicación 2: La forma cristalina de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona de conformidad con la reivindicación 1, caracterizada por un patrón de difracción en polvo de rayos-X usando radiación CuKa que tiene un pico de difracción en ángulo de difracción 2-q de 9.15º en combinación con uno o más picos seleccionados a partir del grupo que consiste de 19.4º, 16.1º, y 16.6º; con una tolerancia para los ángulos de difracción de 0.2 grados.
ARP160103122A 2015-10-23 2016-10-13 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona AR106332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562245391P 2015-10-23 2015-10-23

Publications (1)

Publication Number Publication Date
AR106332A1 true AR106332A1 (es) 2018-01-03

Family

ID=57233858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103122A AR106332A1 (es) 2015-10-23 2016-10-13 Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona

Country Status (13)

Country Link
CN (1) CN108137506A (es)
AR (1) AR106332A1 (es)
AU (1) AU2016341115A1 (es)
CA (1) CA2999332A1 (es)
DO (1) DOP2018000103A (es)
EA (1) EA201890525A1 (es)
EC (1) ECSP18030976A (es)
IL (1) IL257872A (es)
MX (1) MX2018004794A (es)
PE (1) PE20181296A1 (es)
PH (1) PH12018500859A1 (es)
TW (1) TW201725199A (es)
WO (1) WO2017070068A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
AU2019402087B2 (en) * 2018-12-18 2023-04-06 Eli Lilly And Company Dose regimens for use of LY3154207 in the treatment of dopaminergic CNS disorders
TWI825323B (zh) * 2019-06-18 2023-12-11 美商美國禮來大藥廠 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物
EP4304581A1 (en) 2021-03-08 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
CN117337173A (zh) 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途
CN113264926A (zh) * 2021-05-31 2021-08-17 东北林业大学 一种牡荆素与利血平的共晶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236934A (en) * 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
KR20090127307A (ko) * 2007-03-01 2009-12-10 얀센 파마슈티카 엔.브이. 히스타민 ｈ３ 수용체 조절제로서의 테트라하이드로이소퀴놀린 화합물
US20120252853A1 (en) * 2011-04-01 2012-10-04 H. Lundbeck A/S Positive allosteric modulators of nicotinic acetylcholine receptor
JO3316B1 (ar) * 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل

Also Published As

Publication number Publication date
IL257872A (en) 2018-06-03
AU2016341115A1 (en) 2018-04-12
PH12018500859A1 (en) 2018-10-29
ECSP18030976A (es) 2018-05-31
CN108137506A (zh) 2018-06-08
PE20181296A1 (es) 2018-08-07
TW201725199A (zh) 2017-07-16
EA201890525A1 (ru) 2018-09-28
CA2999332A1 (en) 2017-04-27
WO2017070068A1 (en) 2017-04-27
MX2018004794A (es) 2018-06-19
DOP2018000103A (es) 2018-10-31

Similar Documents

Publication Publication Date Title
AR106332A1 (es) Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
BR112017010354A2 (pt) compostos de triazolopirimidina e usos dos mesmos
CL2017002786A1 (es) Referencia cruzada a solicitudes relacionadas
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014001205A1 (es) Compuestos derivados de purina, sus sales y solvatos farmaceuticamente aceptables; composicion farmaceutica que los comprende, util para el tratamiento de un trastorno en el que interviene la modulacion de tlr7, tal como infecciones viricas, trastornos inmunitarios o inflamatorios.
EA201791304A1 (ru) Производные изохинолина для лечения вич
CL2014001049A1 (es) Compuestos derivados de purina sustituida, inhibidores de mtor; composicion farmaceutica; combinacion farmaceutica; uso para el tratamiento o prevencion del cancer, un trastorno neurodegenerativo o una enfermedad oftalmologica.
HK1223923A1 (zh) 用於治療癌症的作為 突變體抑制劑的 -或 -二氨基嘧啶化合物
BR112018005851A2 (pt) derivados de pirrolo[2,3-d]pirimidina como inibidores de dyrk1 / clk1 duais
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
AR095435A1 (es) Formas salinas del (2-(2-(4-fluorofenil)tiazol-4-il)propan-2-il)carbamato de (s)-quinuclidin-3-ilo
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
AR099082A1 (es) Formas sólidas de tenofovir
PE20170674A1 (es) Inhibidores cristalinos de bace
EP3137071A4 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.
AR101109A1 (es) Forma polimórfica del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina
ES2499965B2 (es) Procedimiento de síntesis de compuestos homólogos de azanucleósidos

Legal Events

Date Code Title Description
FB Suspension of granting procedure